LBL-047 prioritized for clinical trials in autoimmune diseases Sjögren's, lupus, and dermatomyositis

Leads Biolabs' partner Dianthus Therapeutics has prioritized LBL-047 for clinical development targeting Sjögren's disease, systemic lupus erythematosus, and dermatomyositis, addressing high unmet medical needs. LBL-047 is a bifunctional fusion protein designed to reduce immune system overactivity by targeting key pathways in autoimmune diseases. A Phase 1 trial started in China in December 2025, with initial results expected in the second half of 2026. Dianthus recently raised $719 million to support global development, aiming to advance LBL-047 as a potential first-line biologic therapy with convenient dosing.